Wang Xiao, Zhang Dan, Li Kang, Guo Peng, Lei Zhi-Xiong
Xiao Wang, Department of Infectious Diseases, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, P.R. China.
Dan Zhang, Department of Infectious Diseases, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, P.R. China.
Pak J Med Sci. 2024 Sep;40(8):1663-1668. doi: 10.12669/pjms.40.8.8982.
To explore the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC).
This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine January 2019 and June 2021 were included. The patients were divided into the control group and the experimental group according to their treatment regimens. The control group received TACE treatment, while the experimental group received TACE combined with targeted therapy. We analyze the relevant data of two groups of patients and evaluate the clinical efficacy and safety of TACE combined with targeted therapy.
The tumor remission rate and control rate in the control group were 41.89% and 75.68%, respectively, while those in the experimental group were 77.63% and 90.79%, with statistically significant differences (p<0.05). The 1-year and 3-year recurrence rates in the control group were 52.71% and 98.65%, respectively, while those in the experimental group were 39.47% and 61.84%, with statistically significant differences (p<0.05). After treatment, the AFP, VEGF, ALT, and AST in the experimental group were significantly reduced compared to the control group (p<0.05). During the treatment period, the incidence and severity of nausea, vomiting, and fever in the experimental group were significantly lower than those in the control group (p<0.05).
The clinical efficacy of TACE combined with targeted therapy for PHC is superior to that of TACE alone, with improved disease control rate, improved long-term survival rate, and good safety.
探讨经动脉化疗栓塞术（TACE）联合靶向治疗原发性肝细胞癌（PHC）的临床疗效及安全性。
本研究为回顾性研究。回顾性选取2019年1月至2021年6月在湖北医药学院附属人民医院收治的150例PHC患者。根据治疗方案将患者分为对照组和试验组。对照组接受TACE治疗，试验组接受TACE联合靶向治疗。分析两组患者的相关数据，评价TACE联合靶向治疗的临床疗效及安全性。
对照组的肿瘤缓解率和控制率分别为41.89%和75.68%，而试验组分别为77.63%和90.79%，差异有统计学意义（p<0.05）。对照组的1年和3年复发率分别为52.71%和98.65%，而试验组分别为39.47%和61.84%，差异有统计学意义（p<0.05）。治疗后，试验组的甲胎蛋白（AFP）、血管内皮生长因子（VEGF）、谷丙转氨酶（ALT）和谷草转氨酶（AST）水平较对照组显著降低（p<0.05）。治疗期间，试验组恶心、呕吐和发热的发生率及严重程度均显著低于对照组（p<0.05）。
TACE联合靶向治疗PHC的临床疗效优于单纯TACE，可提高疾病控制率，改善长期生存率，且安全性良好。
